Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00511004 | Stomach | SIM | negative regulation of binding | 14/708 | 162/18723 | 3.43e-03 | 3.23e-02 | 14 |
GO:00432804 | Stomach | SIM | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 12/708 | 129/18723 | 3.60e-03 | 3.36e-02 | 12 |
GO:190382931 | Stomach | SIM | positive regulation of cellular protein localization | 20/708 | 276/18723 | 4.29e-03 | 3.81e-02 | 20 |
GO:000641411 | Stomach | SIM | translational elongation | 7/708 | 55/18723 | 4.50e-03 | 3.94e-02 | 7 |
GO:000193331 | Stomach | SIM | negative regulation of protein phosphorylation | 23/708 | 342/18723 | 5.72e-03 | 4.67e-02 | 23 |
GO:006109911 | Stomach | SIM | negative regulation of protein tyrosine kinase activity | 5/708 | 31/18723 | 5.72e-03 | 4.67e-02 | 5 |
GO:190336451 | Stomach | SIM | positive regulation of cellular protein catabolic process | 13/708 | 155/18723 | 6.05e-03 | 4.83e-02 | 13 |
GO:000697930 | Thyroid | HT | response to oxidative stress | 81/1272 | 446/18723 | 2.53e-16 | 1.17e-13 | 81 |
GO:004217630 | Thyroid | HT | regulation of protein catabolic process | 70/1272 | 391/18723 | 5.96e-14 | 1.66e-11 | 70 |
GO:000641730 | Thyroid | HT | regulation of translation | 78/1272 | 468/18723 | 1.12e-13 | 2.83e-11 | 78 |
GO:200123330 | Thyroid | HT | regulation of apoptotic signaling pathway | 63/1272 | 356/18723 | 1.87e-12 | 4.01e-10 | 63 |
GO:000030229 | Thyroid | HT | response to reactive oxygen species | 47/1272 | 222/18723 | 1.97e-12 | 4.05e-10 | 47 |
GO:190336230 | Thyroid | HT | regulation of cellular protein catabolic process | 50/1272 | 255/18723 | 7.98e-12 | 1.48e-09 | 50 |
GO:000698627 | Thyroid | HT | response to unfolded protein | 34/1272 | 137/18723 | 2.36e-11 | 3.75e-09 | 34 |
GO:005254729 | Thyroid | HT | regulation of peptidase activity | 71/1272 | 461/18723 | 6.39e-11 | 9.11e-09 | 71 |
GO:200124230 | Thyroid | HT | regulation of intrinsic apoptotic signaling pathway | 37/1272 | 164/18723 | 6.39e-11 | 9.11e-09 | 37 |
GO:009719330 | Thyroid | HT | intrinsic apoptotic signaling pathway | 52/1272 | 288/18723 | 7.65e-11 | 1.06e-08 | 52 |
GO:003596627 | Thyroid | HT | response to topologically incorrect protein | 35/1272 | 159/18723 | 4.27e-10 | 4.95e-08 | 35 |
GO:004254228 | Thyroid | HT | response to hydrogen peroxide | 32/1272 | 146/18723 | 2.66e-09 | 2.64e-07 | 32 |
GO:005254829 | Thyroid | HT | regulation of endopeptidase activity | 64/1272 | 432/18723 | 2.80e-09 | 2.68e-07 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RACK1 | SNV | Missense_Mutation | | c.260N>G | p.Leu87Arg | p.L87R | P63244 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
RACK1 | SNV | Missense_Mutation | novel | c.923N>C | p.Arg308Pro | p.R308P | P63244 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
RACK1 | SNV | Missense_Mutation | | c.357N>T | p.Gln119His | p.Q119H | P63244 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RACK1 | SNV | Missense_Mutation | rs745953408 | c.53N>G | p.Val18Gly | p.V18G | P63244 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RACK1 | SNV | Missense_Mutation | novel | c.32N>C | p.Leu11Pro | p.L11P | P63244 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
RACK1 | SNV | Missense_Mutation | rs745953408 | c.53N>G | p.Val18Gly | p.V18G | P63244 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
RACK1 | insertion | Frame_Shift_Ins | novel | c.819_820insCTTAATTCAAAACTAATTTATTCCTCAGGTCAAAAGTTTTGGGGTGG | p.Val274LeufsTer55 | p.V274Lfs*55 | P63244 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RACK1 | insertion | Nonsense_Mutation | novel | c.799_800insGAGCCTTATCACCAGCTGTTTCTTCCTCAAGGAATACATAACCAC | p.Val267delinsGlyAlaLeuSerProAlaValSerSerSerArgAsnThrTerProLeu | p.V267delinsGALSPAVSSSRNT*PL | P63244 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
RACK1 | deletion | Frame_Shift_Del | novel | c.334delN | p.Ala112ProfsTer73 | p.A112Pfs*73 | P63244 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RACK1 | SNV | Missense_Mutation | novel | c.262N>T | p.Arg88Cys | p.R88C | P63244 | protein_coding | deleterious(0.02) | benign(0.071) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |